Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (61-70 of 418) with videos related to

Pageof 42
Sort By:
The Lancet. Oncology|May 5, 2018
Anti-PD-1 antibody treatment for melanomaAntoni Ribas, John M Kirkwood, Keith T Flaherty
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Tissue-Agnostic Drug DevelopmentKeith T Flaherty, Dung T Le, Steven Lemery
Nature Reviews. Cancer|April 6, 2012
From genes to drugs: targeted strategies for melanomaKeith T Flaherty, F Stephen Hodi, David E Fisher
British Journal of Cancer|January 11, 2018
Mechanisms of resistance to immune checkpoint inhibitorsRussell W Jenkins, David A Barbie, Keith T Flaherty
Current Opinion in Oncology|April 20, 2010
Mutation-driven drug development in melanomaKeith T Flaherty, F Stephen Hodi, Boris C Bastian
Current Opinion in Oncology|February 28, 2008
The MAPK pathway in melanomaLeslie A Fecher, Ravi K Amaravadi, Keith T Flaherty
Experimental Dermatology|May 27, 2015
Feeling energetic? New strategies to prevent metabolic reprogramming in melanomaDaniel Verduzco, Keith T Flaherty, Keiran S M Smalley
Cell Cycle (Georgetown, Tex.)|June 4, 2015
YAP in MAPK pathway targeted therapy resistanceKeith T Flaherty, Jennifer A Wargo, Trever G Bivona
Nature Reviews. Cancer|October 13, 2020
Author Correction: From genes to drugs: targeted strategies for melanomaKeith T Flaherty, F Stephen Hodi, David E Fisher
JAMA Oncology|August 14, 2015
Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab TherapyJennifer A Lo, David E Fisher, Keith T Flaherty
Pageof 42

Showing results (61-70 of 418) with videos related to

Sort By:
Pageof 42
The Lancet. Oncology|May 5, 2018
Anti-PD-1 antibody treatment for melanomaAntoni Ribas, John M Kirkwood, Keith T Flaherty
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Tissue-Agnostic Drug DevelopmentKeith T Flaherty, Dung T Le, Steven Lemery
Nature Reviews. Cancer|April 6, 2012
From genes to drugs: targeted strategies for melanomaKeith T Flaherty, F Stephen Hodi, David E Fisher
British Journal of Cancer|January 11, 2018
Mechanisms of resistance to immune checkpoint inhibitorsRussell W Jenkins, David A Barbie, Keith T Flaherty
Current Opinion in Oncology|April 20, 2010
Mutation-driven drug development in melanomaKeith T Flaherty, F Stephen Hodi, Boris C Bastian
Current Opinion in Oncology|February 28, 2008
The MAPK pathway in melanomaLeslie A Fecher, Ravi K Amaravadi, Keith T Flaherty
Experimental Dermatology|May 27, 2015
Feeling energetic? New strategies to prevent metabolic reprogramming in melanomaDaniel Verduzco, Keith T Flaherty, Keiran S M Smalley
Cell Cycle (Georgetown, Tex.)|June 4, 2015
YAP in MAPK pathway targeted therapy resistanceKeith T Flaherty, Jennifer A Wargo, Trever G Bivona
Nature Reviews. Cancer|October 13, 2020
Author Correction: From genes to drugs: targeted strategies for melanomaKeith T Flaherty, F Stephen Hodi, David E Fisher
JAMA Oncology|August 14, 2015
Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab TherapyJennifer A Lo, David E Fisher, Keith T Flaherty
Pageof 42